Investigator Steven O’Day of the Angeles Clinic and Research Institute in California still hopes to push ahead with a Phase III study of Roche’s Avastin in melanoma, despite the drug missing its goal in a Phase II trial presented at the ECCO-ESMO cancer conference.
Ben Hirschler
Ben Hirschler’s Profile
TrackbackPost Your Comment
House Rules:
- We moderate all comments and will publish everything that advances the post directly or with relevant tangential
- We try not to publish comments that we think are offensive or appear to pass you off as another person, and we will be conservative if comments may be considered libelous.information.
